Achilles Therapeutics Total Debt vs. EBITDA
| ACHL Stock | USD 1.08 0.01 0.93% |
For Achilles Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Achilles Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Achilles Therapeutics PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Achilles Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Achilles Therapeutics PLC over time as well as its relative position and ranking within its peers.
Achilles |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Achilles Therapeutics PLC EBITDA vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Achilles Therapeutics's current stock value. Our valuation model uses many indicators to compare Achilles Therapeutics value to that of its competitors to determine the firm's financial worth. Achilles Therapeutics PLC is rated below average in total debt category among its peers. It also is rated below average in ebitda category among its peers . The company's current value of EBITDA is estimated at (73.96 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Achilles Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Achilles Total Debt vs. Competition
Achilles Therapeutics PLC is rated below average in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 135.21 Million. Achilles Therapeutics holds roughly 4.62 Million in total debt claiming about 3% of equities under Health Care industry.
Achilles EBITDA vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Achilles Therapeutics |
| = | 4.62 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Achilles Therapeutics |
| = | (70.44 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Achilles EBITDA Comparison
Achilles Therapeutics is currently under evaluation in ebitda category among its peers.
Achilles Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Achilles Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Achilles Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Achilles Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Achilles Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -13.1 M | -12.4 M | |
| Net Loss | -64.1 M | -60.9 M | |
| Operating Income | -75.3 M | -79 M | |
| Net Loss | -75.1 M | -78.8 M | |
| Income Before Tax | -69.2 M | -72.6 M | |
| Total Other Income Expense Net | 6.1 M | 3.7 M | |
| Net Loss | -69.9 M | -66.4 M | |
| Income Tax Expense | 491 K | 515.5 K | |
| Change To Netincome | 16 M | 16.8 M | |
| Net Loss | (1.74) | (1.83) | |
| Income Quality | 0.69 | 0.99 | |
| Net Income Per E B T | 1.01 | 0.80 |
Achilles Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Achilles Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Achilles Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Achilles Therapeutics' important profitability drivers and their relationship over time.
Use Achilles Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Achilles Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will appreciate offsetting losses from the drop in the long position's value.Achilles Therapeutics Pair Trading
Achilles Therapeutics PLC Pair Trading Analysis
The ability to find closely correlated positions to Achilles Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Achilles Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Achilles Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Achilles Therapeutics PLC to buy it.
The correlation of Achilles Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Achilles Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Achilles Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Achilles Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Achilles Therapeutics position
In addition to having Achilles Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Providers Thematic Idea Now
Insurance Providers
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
To fully project Achilles Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Achilles Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Achilles Therapeutics' income statement, its balance sheet, and the statement of cash flows.